List your practice on InjuredCare | Log in / Sign up



Anzemet is the brand name for the anti-nausea medication dolasetron mesylate, used to mitigate the side effects of chemotherapy. Azemet has been connected to severe and even lethal side effects of its own. Anzemet was approved by the FDA in September 1997 for the treatment of chemotherapy-related nausea and vomiting. The FDA and other national governments have intervened in the use of Anzemet injections after finding connections to a rare and highly dangerous heart disorder.

Cancer Patients Have Experienced These Dangerous Anzemet Side-Effects

  • Lethal heart abnormality – torsade de pointes – which presents as an irregular heartbeat and is highly lethal if not identified and treated immediately
  • Pounding and/or rapid heartbeats
  • A sense of general faintness and illness
  • Chest pain that can spread throughout arms
  • Fainting
  • A slowing in heartbeat

In December 2010, the FDA issued a release stating that Anzamet injections should not be utilized for chemotherapy patients looking to reduce symptoms of nausea and vomiting. The statement was made following the analysis of data summarizing the correlation between Anzamet injections and the development of the dangerous heart condition torsade de pointes.

Canada withdrew Anzemet's intravenous injection from their markets on May 10, 2011, after observing the connection between Anzemet and an increased risk of arrythmia that can lead to serious cardiac issues in cancer patients.

Studies also establish a connection between the oral version of Anzemet and arrhythmic cardiac responses in cancer patients.

Related Articles

  • Drug and Medical Device Injuries

    Drug and Medical Device Injuries

    Certain pharmaceutical drugs and medical devices have been linked to cancer, stroke, internal bleeding, and a number of other medical conditions. Opioid addiction has become a wide Read More...

  • Power Morcellators

    Power Morcellators

    Power morcellators are devices used in the tearing (morcellating) of tissue during arthroscopic procedures. Power morcellators were approved for use by the FDA in 1991. One common Read More...

  • Pradaxa


    The Trade or Brand Name for the Anticoagulant Dabigatran First approved by the U.S. Food and Drug Administration (FDA) in October 2010, dabigatran is used primarily to treat and p Read More...

© 2015-2022 LawConnect, Inc. All rights reserved.